NCT03866382 2026-04-16
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
201 trialsNCT05663710 2026-04-16
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
NCT03810651 2026-04-15
Pencil Beam Scanning in Patients With Renal Tumors
Children's Hospital of Philadelphia
Phase EARLY_PHASE1 Recruiting
NCT04693377 2026-04-15
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT05581004 2026-04-15
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT06026410 2026-04-14
FIT-001
Kura Oncology, Inc.
Phase 1 Recruiting
NCT06053658 2026-04-14
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06525831 2026-04-14
Rein3DP-M
University Hospital, Bordeaux
Phase NA Recruiting
NCT07195916 2026-04-14
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
Phase 1 Recruiting
NCT04895709 2026-04-13
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT05969496 2026-04-13
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT06582017 2026-04-13
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
Phase 1 Recruiting
NCT07227402 2026-04-13
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05048212 2026-04-09
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06835972 2026-04-09
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT07419841 2026-04-09
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
Phase 1 Recruiting
NCT05327686 2026-04-08
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT07402109 2026-04-08
CT-STARRS
Erasmus Medical Center
Phase NA Recruiting
NCT07517198 2026-04-08
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
Phase 1 Recruiting
NCT04981509 2026-04-07
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05665361 2026-04-07
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06444815 2026-04-07
STEALTH-001
KaliVir Immunotherapeutics
Phase 1 Recruiting
NCT06661720 2026-04-07
STRIKE
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT07195682 2026-04-07
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Bristol-Myers Squibb
Phase 1 Recruiting
NCT07227415 2026-04-07
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
Phase 1/2 Recruiting
NCT02830724 2026-04-06
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06376669 2026-04-03
SPARE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06500455 2026-04-03
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
Phase 3 Recruiting
NCT06863311 2026-04-03
EXACT
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT07188896 2026-04-03
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06147037 2026-04-02
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Recruiting
NCT06222593 2026-04-01
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC
State University of New York at Buffalo
Phase 1/2 Recruiting
NCT07197580 2026-04-01
LUTEON
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT05267626 2026-03-31
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT07293351 2026-03-31
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT07405164 2026-03-31
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03786796 2026-03-30
ORCHID
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05536141 2026-03-30
ARC-20
Arcus Biosciences, Inc.
Phase 1 Recruiting
NCT05837767 2026-03-30
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT04235777 2026-03-27
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05024214 2026-03-25
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
3D Medicines
Phase 1/2 Recruiting
NCT07123090 2026-03-25
SPARCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05733715 2026-03-24
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Recruiting
NCT03221335 2026-03-20
EUS-guided RFA for Solid Abdominal Neoplasms
Chinese University of Hong Kong
Phase NA Recruiting
NCT07049926 2026-03-20
MK-3475-03C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07397611 2026-03-20
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06391099 2026-03-19
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Phase NA Recruiting